Form 4: AnaptysBio CFO Dennis Mulroy Acquires 20,000 Shares Through Performance Stock Units

Dennis Mulroy, CFO of AnaptysBio, Inc., acquired 20,000 shares of common stock on July 22, 2024, through the vesting of performance stock units (PSUs).

Summary

• On July 22, 2024, Dennis Mulroy, the Chief Financial Officer of AnaptysBio, Inc., acquired 20,000 shares of the company's common stock.
• This acquisition was a result of the vesting of performance stock units (PSUs).
• Each PSU represents a contingent right to receive one share of AnaptysBio's common stock upon the achievement of certain share price metrics.
• 50% of the shares subject to the PSU that meet the performance metrics will vest on the later of (i) the 1-year anniversary of the achievement and (ii) July 1, 2026.
• The remaining 50% will vest on the 2-year anniversary of the achievement, but no later than July 1, 2028, contingent on Mulroy's continued service to the company.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects the achievement of performance metrics and aligns management's interests with shareholders. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The vesting of PSUs indicates that performance metrics related to the share price may have been achieved, which could be seen as a positive signal.
• The vesting schedule incentivizes the CFO to remain with the company for the long term.

Risks

• The vesting of the remaining shares is contingent on the CFO's continued service, creating a potential risk if the CFO were to leave the company before the vesting dates.

Future Outlook

The future vesting of the remaining PSU shares is contingent on the achievement of further performance metrics and the CFO's continued service to the company.

Industry Context

Stock-based compensation, including PSUs, is a common practice in the biotechnology industry to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Many biotech companies use performance-based equity awards to incentivize executives.
• The specific performance metrics tied to AnaptysBio's PSUs (share price) are a common approach to align executive compensation with shareholder returns.
• Companies like Amgen, Regeneron, and Gilead also utilize similar equity compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the vesting of PSUs as a positive sign, indicating that the company is achieving its performance goals.
• Employees may be motivated by the fact that executives are incentivized to improve the company's performance.

Key Dates